LabMinds Secures Financing to Boost Commercial Growth of The REVO® Robotic System

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

LabMinds, Inc., an award-winning robotics company in life sciences, today announced it has closed a fully subscribed funding round from a mix of private and strategic investors. The round was closed at a 20% higher share price than the funding round completed in 2019, reflecting the substantial progress the company has made. This funding will help drive the commercialization of its automation system as well as facilitate the expansion of LabMinds’ product portfolio.

“We are pleased to announce the completion of a fully subscribed funding round,” said Jeff Caputo, President & CEO of LabMinds, Inc. “We appreciate the support and excitement by our existing and new investors. Not only do they recognize the large market opportunity for this innovative technology, they also acknowledge the considerable value it brings to the drug development process especially during these challenging times. Our REVO automation system ensures reliability, traceability and consistency which are critical for solution preparation.”

“Our team at LabMinds continues to build traction within the bio-pharma world, with multiple large customers moving toward using The REVO platform to standardize processes,” said John Kawola, Chairman of the Board, LabMinds. “Automation in solution preparation has been lacking. The REVO fills this gap and accelerates drug development while saving time and money for our customers. The Board and Investors are excited to continue to support the Company’s growth.”

LabMinds’ customers have been taking full advantage of The REVO and its automation capabilities to help with rapid COVID-19 drug discovery and development as well as facilitate remote operations.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.